Join Daniel Dowd, PharmD, for a free webinar to review the genetic variations that can predispose certain patients towards specific behavior and mental health conditions. You’ll learn about BDNF, COMT, SLC6A4, and CRHR1; the mechanisms by which these variants can create a bias, and more!




Overview

It is well established that our behaviors are influenced by our environment, experiences, and genetics. While most genes have a very small influence on behaviors, some can create a predisposition towards certain characteristics or traits. In this webinar, Dr. Daniel DowdGenomind’s Senior Vice President of Medical Affairs, discusses genes such as BDNF, COMT, SLC6A4 and CRHR1 and the mechanisms by which these variants can create a bias towards some behaviors. He also discusses supplements that may target the biochemistry associated with these genes.

Prescribers > Attend this webinar and get a FREE Genomind PGx test kit! If you were unable to attend the webinar, but would like the free test, please email Heather at [email protected] by December 31st to get the free test offer details. The free test is only available to prescribers. You must provide licensing credentials at the time of the test order.

This webinar is sponsored by Genomind, whose mission is to optimize the treatment experience for individuals and healthcare providers by unlocking the value of precision medicine through actionable genetic insights and innovative health technology. Learn more about Genomind below!

Watch the Lecture Now

Instructor

Daniel Dowd, PharmD

Dr. Daniel Dowd is Genomind’s Chief Clinical Officer. His responsibilities at Genomind include building and managing a mental health medical affairs team of PharmDs and PhDs. Dr. Dowd is also intimately involved with product development, genetic research, medical education programs and pharmacy integrations. He is a PharmD licensed in New York and New Jersey and has over 15 years of unique experience across community pharmacy management, medical affairs and healthcare education. Prior to joining Genomind, Dr. Dowd held positions as district and regional director of community pharmacy training and operations for several pharmacies including Rite Aid and A&P. For 13 years, he also developed and taught advanced pharmacology courses at the City University of New York (CUNY). Dr. Dowd has published on the implementation of pharmacogenetics in psychiatry and has been interviewed by national media outlets, including Drug Topics, JAMA Medical News and Perspectives and the Dr. Oz show. He is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the American Society of Pharmacovigilance STRIPE Collaborative Community.

Our mission is to optimize the treatment experience for individuals and healthcare providers by unlocking the value of precision medicine through actionable genetic insights and innovative health technology.

 

Every year millions of people struggle through trial-and-error treatment or encounter preventable health complications due to adverse drug events. Annually, the societal costs to the healthcare industry are over $358 billion. Until recently, the information to help reduce guesswork, identify adverse drug events, and make personalized treatment decisions was lacking.

There is no one-size-fits all treatment, and Genomind’s platform was developed to unlock the potential of truly personalized medicine. With our comprehensive precision health platform, healthcare providers can quickly assess drug-drug, gene-drug, and drug-drug-gene interactions to deliver safer and more targeted approaches to treatment.

While our heritage is rooted in mental health PGx testing, we have grown to include a broader scope of conditions. Keeping a keen focus on the customer experience and maintaining a deep understanding of challenges faced in our health system, we create innovative solutions that make a meaningful difference in the lives of millions. Together, we can reduce costs, improve quality of care and increase patient and healthcare provider satisfaction.

That’s the science behind better.